Table 1. Survival analysis using Cox regression.
Risk factors | Univariate analysis | Multivariate analysis | |||
---|---|---|---|---|---|
HR (95% CI) | P | HR (95% CI) | P | ||
Demographic characteristics | Age at CD diagnosis (years) | 1.03 (0.99–1.08) | 0.15 | ||
Gender, male (n) | 0.29 (0.08–1.06) | 0.06 | 0.32 (0.09–1.16) | 0.08 | |
HV variate (n) | 0.90 (0.29–2.76) | 0.85 | |||
The same side of the diaphram (n) | 0.04 (0.00–42.18) | 0.36 | |||
*Chronic diseases (n) | 1.06 (0.29–3.85) | 0.94 | |||
Hepatitis virus infection (n) | 1.44 (0.19–11.08) | 0.73 | |||
Prior history of TB (n) | 4.51 (1.23–16.47) | 0.02 | 2.66 (0.67–10.55) | 0.16 | |
Development delay (n) | 0.05 (0.00–8073.10) | 0.62 | |||
POEMS (n) | 3.03 (1.01–9.04) | 0.047 | 2.01 (0.55–7.37) | 0.29 | |
ECOG ≥ 1 | 25.98 (0.02–33441.67) | 0.37 | |||
Symptoms & signs | B symptom (n) | 5.05 (0.65–38.98) | 0.12 | ||
**Generalized symptoms (n) | 1.00 (0.13–7.71) | 1.00 | |||
Shortness of breath (n) | 2.15 (0.72–6.43) | 0.17 | |||
Rash (n) | 1.97 (0.66–5.87) | 0.22 | |||
Adenopathy (n) | 2.79 (0.36–21.48) | 0.33 | |||
System involvement | ***eGFR< 60 ml/min (n) | 4.89 (1.63–14.73) | 0.005 | 4.60 (1.50–14.12) | 0.008 |
Nephrotic syndrome (n) | 0.05 (0.000–6256.44) | 0.61 | |||
Pulmonary involvment (n) | 1.51 (0.49–4.65) | 0.47 | |||
Paraneoplastic pemphigus (n) | 1.88 (0.24–14.68) | 0.55 | |||
Laboratory tests | WBC (10^9/L) | 1.10 (0.94–1.29) | 0.22 | ||
Hb (g/L) | 1.01 (0.99–1.03) | 0.21 | |||
Platelet (10^9/L) | 1.00 (0.99–1.00) | 0.90 | |||
Positive urine protein (n) | 0.78 (0.23–3.05) | 0.79 | |||
Positive fecal occult blood (n) | 2.84 (0.36–22.32) | 0.32 | |||
Serum albumin (g/L) | 0.94 (0.87–1.02) | 0.16 | |||
Tbil (umol/L) | 0.97 (0.82–1.14) | 0.68 | |||
ALP (U/L) | 0.99 (0.98–1.01) | 0.28 | |||
LDH (U/L) | 1.00 (0.99–1.01) | 0.81 | |||
hsCRP (mg/L) | 0.99 (0.97–1.01) | 0.19 | |||
ANA positive (n) | 0.03 (0.00–24.59) | 0.32 | |||
HbsAg positive (n) | 1.82 (0.23–14.07) | 0.57 | |||
HCV positive (n) | 0.05 (0.00–7145.0) | 0.80 | |||
EBV–DNA positive (n) | 0.04 (0.00–12940.0) | 0.75 | |||
CMV–DNA positive (n) | 0.04 (0.00–12940.0) | 0.75 | |||
M–protein positive (n) | 2.08 (0.70–6.21) | 0.19 |
CD, Castleman’s disease; HV, hyaline–vascular; TB, tuberculosis; POEMS, polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, skin changes; ECOG, Eastern Cooperative Oncology Group; WBC, white blood cell; Hb, hemoglobin; Tbil, total bilirubin; ALP, alkaline phosphatase; LDH, lactate dehydrogenase; hsCRP, hypersensitive c-reactive protein; ANA, anti-nuclear antibodies; HbsAg, hepatitis B surface antigen; HCV, hepatitis C; EBV, Epstein-Barr Virus; CMV, cytomegalovirus.
*Chronic disease: hypertension, diabetes, coronary heart disease, chronic liver disease, chronic kidney disease; **B symptom: fever, night sweats, weight loss; ***Generalized symptom: fatigue, malaise, appetite, pain; ****eGFR: estimated glomerular filtration rate with Modification of Diet in Renal Disease (MDRD) equation.